Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
Abstract Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially o...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/4b94adbd323b4bf69ee418f876c26582 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|